Glaukos (NYSE:GKOS) Price Target Raised to $175.00

Glaukos (NYSE:GKOS) had its price objective raised by equities researchers at Stifel Nicolaus from $153.00 to $175.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Stifel Nicolaus’ price objective points to a potential upside of 17.05% from the company’s current price.

GKOS has been the subject of several other reports. Wells Fargo & Company boosted their price objective on Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Monday, December 2nd. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, UBS Group assumed coverage on Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $147.75.

Glaukos Trading Down 1.1 %

GKOS opened at $149.51 on Tuesday. The firm’s fifty day moving average is $140.52 and its two-hundred day moving average is $129.79. The firm has a market cap of $8.24 billion, a PE ratio of -49.51 and a beta of 1.03. Glaukos has a twelve month low of $74.75 and a twelve month high of $153.50. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter last year, the business posted ($0.50) EPS. The firm’s revenue was up 23.9% compared to the same quarter last year. Equities research analysts anticipate that Glaukos will post -1.89 EPS for the current year.

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,603 shares of company stock worth $2,605,678. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Values First Advisors Inc. acquired a new position in shares of Glaukos in the third quarter valued at approximately $25,000. Harvest Fund Management Co. Ltd increased its position in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares during the period. KBC Group NV lifted its holdings in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares in the last quarter. EWA LLC acquired a new position in shares of Glaukos in the third quarter valued at about $209,000. Finally, Procyon Advisors LLC bought a new position in Glaukos during the third quarter worth about $210,000. 99.04% of the stock is owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.